This website is intended for US Healthcare Professionals.

Clinical Trials

Explore Arvinas-Sponsored Clinical Trials 

Find trials that may be relevant for you and your patients. 

Arvinas Development Program
Explore our development pipeline of PROTAC® protein degraders.

Enrolling Oncology Clinical Trials

Learn more about our enrolling clinical trials.

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.


Vepdegestrant vs fulvestrant in previously treated ER+/HER- advanced or metastatic breast cancer 

Vepdegestrant plus palbociclib vs letrozole plus palbociclib in previously untreated ER+/HER- advanced breast cancer

An umbrella study of vepdegestrant plus other anticancer therapies in ER+ advanced or metastatic breast cancer

A phase 1b/2 open-label study of vepdegestrant (ARV-471) in combination with PF-07220060 (a CDK4 inhibitor) in patients with ER+/HER2- advanced or metastatic breast cancer


ARV-766 alone or in combination with abiraterone in previously treated metastatic prostate cancer


ARV-393 in adult patients with advanced non-Hodgkin lymphoma

Prostate Cancer


A phase 1/2 open-label study of ARV-766 in patients with metastatic castration-resistant prostate cancer and progression on prior systemic therapies

Arvinas Oncology Medical

You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to